CLINICAL TRIALS PROFILE FOR LIORESAL
✉ Email this page to a colleague
All Clinical Trials for LIORESAL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00373295 ↗ | Effect of Baclofen on Marijuana Withdrawal and Relapse | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 2006-05-01 | The purpose of this study is to determine if baclofen dose-dependently decreases marijuana's direct effects and symptoms of marijuana withdrawal and thus decreases marijuana relapse. |
| NCT00373295 ↗ | Effect of Baclofen on Marijuana Withdrawal and Relapse | Completed | New York State Psychiatric Institute | Phase 2 | 2006-05-01 | The purpose of this study is to determine if baclofen dose-dependently decreases marijuana's direct effects and symptoms of marijuana withdrawal and thus decreases marijuana relapse. |
| NCT00597701 ↗ | Treating Alcohol Withdrawal With Oral Baclofen | Completed | Essentia Health | N/A | 2003-04-01 | The purpose of this study is determine if subjects with alcohol withdrawal who receive oral baclofen, plus standard benzodiazepine therapy, will experience less severe withdrawal symptoms than those who receive placebo plus standard benzodiazepine therapy.Subjects with alcohol withdrawal syndrome(AWS)who receive baclofen plus standard benzodiazepine therapy will experience fewer complications of AWS (as measured by use of additional sedatives, restraints, and/or intensive care unit [ICU] admissions) compared with subjects who receive placebo plus standard benzodiazepine therapy. |
| NCT00607542 ↗ | Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1/Phase 2 | 2008-11-01 | Oral baclofen is used commonly to treat spasticity in children with cerebral palsy. Although for adults there is dosing,safety and efficacy information in the package insert, this is not the case for children. The purpose of this study is to determine how fast the drug is cleared from the body, the correct dose, and long-term safety and efficacy for children with spasticity. |
| NCT00812851 ↗ | Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS) | Completed | ALS Association | N/A | 2005-04-01 | Many patients with ALS experience cramps during the course of the disease. Frequently, cramps occur as the first symptom of the disease, months before the patients notice weakness and wasting. Cramp severity varies from mild, without affecting daily activities and sleep, to disabling, where almost any voluntary muscle activity induces long standing, severely painful cramping. ALS patients who smoke herbal cannabis (marijuana) or drink hemp tea report lessening of cramps and fasciculations. Although, various medications, such as magnesium, quinine sulfate, lioresal, dantrolene, clonazepam, diphenylhydantoin and gabapentin are used for the treatment of cramps in ALS so far, no medication has been of proven benefit. However, a recent pilot study with THC in ALS showed symptomatic effects in "spasms", fasciculations, insomnia and appetite. The aim of the proposed study is to determine the tolerability, safety and efficacy of THC in the treatment of cramps in ALS. The hypothesis is that THC will lessen cramps in ALS. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LIORESAL
Condition Name
Clinical Trial Locations for LIORESAL
Trials by Country
Clinical Trial Progress for LIORESAL
Clinical Trial Phase
Clinical Trial Sponsors for LIORESAL
Sponsor Name
